Linden Thomas Advisory Services LLC Sells 118 Shares of Humana Inc. (NYSE:HUM)

Linden Thomas Advisory Services LLC decreased its position in shares of Humana Inc. (NYSE:HUMFree Report) by 6.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,647 shares of the insurance provider’s stock after selling 118 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Humana were worth $418,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HUM. International Assets Investment Management LLC increased its position in Humana by 261,025.1% during the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after buying an additional 738,701 shares during the period. FMR LLC grew its holdings in shares of Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Humana by 55.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after purchasing an additional 214,535 shares in the last quarter. Pzena Investment Management LLC grew its holdings in shares of Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Humana during the 3rd quarter worth $50,102,000. Institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

HUM has been the topic of several analyst reports. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. UBS Group reduced their target price on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, October 4th. Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, Royal Bank of Canada reduced their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $297.68.

Check Out Our Latest Stock Analysis on HUM

Humana Price Performance

Shares of HUM opened at $294.47 on Monday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $35.46 billion, a price-to-earnings ratio of 26.08, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. The business has a 50-day moving average of $274.39 and a 200-day moving average of $304.79.

Humana (NYSE:HUMGet Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. As a group, equities research analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.32% of the stock is currently owned by corporate insiders.

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.